---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence. Covers REVEAL pivotal, ASPIRE, and REVEAL part A. 146 evidence topics quoted from 44 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 REVEAL Pivotal

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registered objectives of NCT05606614

> “The primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the efficacy and safety of TSHA-102 at the selected dose.”
> “REVEAL Part B (Phase 3) will evaluate the efficacy and safety of TSHA-102 at the dose level 2 determined in Part A in 15 females ages 6 to <22 years with typical Rett syndrome.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.1-2"></a>

###### Role of the pivotal trial in the development plan

> “The TSHA-102 clinical development program is designed to support the potential future approval of TSHA-102 for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.”
> “In close collaboration with the FDA we designed the TSHA-102 pivotal program so that efficacy data from the REVEAL pivotal trial in patients aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE trial to support the potential for a broad label for TSHA-102.”
> “Developmental milestones are defined as a functional gain of one or more of the 28 milestones defined in the natural history study. This is the primary evidence of efficacy that will support our planned BLA submission and the FDA’s review of efficacy in the REVEAL pivotal trial.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Country of the pivotal trial

> “The trial is taking place in the United States.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.2-2"></a>

###### Registered sites for NCT05606614 (Parts A and B combined)

| Site | Registry record |
| --- | --- |
| Duarte, California, United States | “City of Hope” |
| La Jolla, California, United States | “UC San Diego” |
| Oakland, California, United States | “UC San Francisco Benioff Children's Hospital” |
| Chicago, Illinois, United States | “Rush University Medical Center” |
| Baltimore, Maryland, United States | “Kennedy Krieger Institute” |
| Boston, Massachusetts, United States | “Boston Children's Hospital” |
| St Louis, Missouri, United States | “Washington University, St. Louis” |
| Dallas, Texas, United States | “UT Southwestern Children's Medical Center” |
| Montreal, Quebec, Canada | “CHU St. Justine” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.2-3"></a>

###### Site activation after regulatory feedback

> “Taysha commenced site activation for the REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of a NOL from Health Canada and written feedback from the FDA”

Source: [Taysha Gene Therapies second quarter 2025 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm)

<a id="topic-3.1.1.2-4"></a>

###### First participant dosed

> “In December 2025, the Company dosed the first patient with TSHA-102 in the Phase 1/2 Part B REVEAL pivotal trial and therefore triggered a milestone payment in connection with the Abeona Rett Agreement.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.2-5"></a>

###### Completion of dosing

> “Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6-month interim”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.2-6"></a>

###### Anticipated interim data

> “Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Single-arm, open-label design with participants as their own control

> “The REVEAL pivotal trial, also known as Part B, is a single-arm, open-label study evaluating the efficacy and safety of high dose TSHA-102 as a single lumbar intrathecal administration in females aged 6 to <22 years with Rett syndrome due to MECP2 loss-of-function mutation, with each patient serving as their own control.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.3-2"></a>

###### Registry design: phase 1/2/3 record with outcome assessor masking

> “An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome”
> “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.”
> “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.3-3"></a>

###### FDA written alignment on key design elements

> “Written alignment from FDA supports single-arm, open label pivotal trial with primary endpoint of developmental milestone gain/regain in the developmental plateau population (≥ 6 years, intend N=15) with each patient serving as their own control”
> “12-month primary analysis, and intend to perform a 6-month interim analysis”
> “The FDA advised the Company to submit the pivotal Part B trial protocol and the associated SAP as an amendment to its IND application, eliminating the need for formal end-of-phase meeting”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

<a id="topic-3.1.1.3-4"></a>

###### Finalized protocol and statistical analysis plan with a 6-month interim analysis

> “Additionally, the Company announced that it has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan (SAP) that are intended to support the planned Biologics License Application (BLA) submission for TSHA-102, following the resolution of remaining clinical and statistical queries.”
> “Inclusion of a 6-month interim analysis that may serve as the basis for BLA submission: enabled by the rigorous, objective evaluation criteria used to evaluate developmental milestone achievement in Part A of the REVEAL Phase 1/2 trials and the unprecedented 83% response rate seen at six months following high dose TSHA-102 (5 out of 6 patients; May 2025 data cutoff) in Part A that deepened over time”

Source: [Taysha Gene Therapies Breakthrough Therapy designation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525227505/d61846dex991.htm)

<a id="topic-3.1.1.3-5"></a>

###### Natural history external reference: Rett Syndrome Natural History Study

> “The purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT including the range of clinical involvement and to correlate genotype-phenotype over a broad spectrum of phenotypes.”
> “This study will not include clinical trials, but should set the stage for such trials and other translational research projects (e.g., development of biomarkers).”

Source: [ClinicalTrials.gov NCT02738281](https://clinicaltrials.gov/study/NCT02738281)

<a id="topic-3.1.1.3-6"></a>

###### Natural history external reference: trial-aligned analysis cohort and simulated control cohorts

> “The RNHS dataset comprises 1870 individuals.”
> “1191 (63.7%) participants were included, with a mean (SD) age at first study visit of 10.2 (9.3) years (Table 1)”
> “Participants were female with typical RTT and confirmed MECP2 mutation; inclusion/exclusion criteria were aligned to those typically used in interventional RTT trials”
> “Using RNHS participants in the developmental plateau (age ≥6 years) cohort, bootstrap simulations (10,000 iterations) were used to generate trial-like untreated cohorts (N=15; 1-year follow-up) via repeated sampling of the RNHS analysis cohort under prespecified assumptions”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Reasons given for not using a concurrent control

> “Trial design challenges are compounded when evaluating an investigational gene therapy for RTT due to ethical and methodological concerns with sham controls (e.g., lumbar puncture without active agent), potential functional unblinding from required immunosuppression, and delayed-treatment control designs that may expose participants to unjust harm by postponing intervention during critical neurodevelopmental windows”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.3-8"></a>

###### FDA draft guidance on single-arm trials using participants as their own control

> “This design leverages an internal, baseline control strategy where a participant’s response to therapy on a given measure is compared to their baseline status on that measure.”
> “Self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals, and the intervention is expected to lead to improvement.”
> “Finally, the selection of objectively measured endpoints that are not effort-dependent is critical to interpreting results from self-controlled or other non-blinded trials.”

Source: [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download)

<a id="topic-3.1.1.3-9"></a>

###### Blinded central rating of pre- and post-treatment videos

> “Pre- and post-treatment videos are evaluated by centralized, blinded raters using a standardized process to ensure consistent, objective evaluations of prespecified milestone demonstrations.”
> “Raters are highly trained clinical psychologists/physical therapists with experience in RTT.”
> “Bias Mitigation Strategy: Blinded central rating includes pre- and post-treatment videos in each package.”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Registered inclusion and exclusion criteria

| Criterion | Registry record |
| --- | --- |
| Age and sex (inclusion) | “females between the ages of 6 and <22 in Part B (pivotal cohort).” |
| Diagnosis (inclusion) | “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.” |
| Blood products (inclusion) | “Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed.” |
| Residence near the site (inclusion) | “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment” |
| Other neurodevelopmental disorder (exclusion) | “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.” |
| Brain injury or early abnormal development (exclusion) | “Participant has a history of brain injury that causes neurological problems or had grossly abnormal psychomotor development in the first 6 months of life.” |
| Atypical Rett syndrome (exclusion) | “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.” |
| Ventilation (exclusion) | “Participant requires invasive ventilatory support.” |
| Additional criteria | “Other protocol defined inclusion/exclusion criteria may apply” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.4-2"></a>

###### Developmental plateau population aged 6 years and older

> “The study enrolled females in the developmental plateau population of Rett syndrome; these patients have an exceedingly low likelihood (0% to <6.7%) of gaining new or regaining developmental milestones that were lost after a defined number of years, based on our analysis of the National Institutes of Health, or NIH, -funded International Rett Syndrome Foundation’s natural history study data.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.4-3"></a>

###### Rationale for the minimum age of 6 years

> “Before 6 years of age, milestone gain, loss, and regain were more variable and less predictable, with spontaneous first-time gain for a single milestone as high as 97%; inclusion of younger participants without explicit age accounting could increase background spontaneous gain and thereby increase type I error”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.4-4"></a>

###### Milestone-level eligibility at screening and baseline

> “Criteria required for a milestone to be considered eligible for gain/regain”
> “Medical history confirmation the milestone was either never achieved or lost sufficiently long ago”
> “In-clinic video assessment confirmation milestone was not demonstrated”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Registered intervention and arm

> “TSHA-102 at Selected Dose (Dose Level 2): 1.0 × 10¹⁵ total vector genomes (vg)”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (1.0 × 10¹⁵) (fully enrolled, 17 participants).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.5-2"></a>

###### Single lumbar intrathecal administration of the high dose

> “Each participant will receive a single administration of the high dose (1x1015 total vg) of TSHA-102 delivered by lumbar intrathecal injection.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

###### Dose selection from Part A

> “The maximum tolerated dose, or MTD, or maximum administered dose, or MAD, established in Part A will be administered during dose expansion in Part B, which is the pivotal phase of the trials.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Rett Syndrome Developmental Milestone Assessment Response as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary outcome of Part B

| Outcome | Registry record | Time frame |
| --- | --- | --- |
| Primary (Part B) | “Change from baseline in percentage of participants who gain or regain any one or more of the 28 items from the Developmental Milestones Assessment (DMA), which are video recorded and scored by independent, blinded central raters.” | “Baseline through Week 52” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint definition and key secondary endpoints

> “The primary endpoint will assess response rate, defined as the percentage of patients who gain or regain at least one developmental milestone from a list of 28 natural-history defined milestones across the core functional domains of communication, fine motor and gross motor, following administration of TSHA-102.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

> “Key secondary endpoints in the REVEAL pivotal trial include the average number of total developmental milestones gained or regained per patient following TSHA-102, as well as clinician-assessed outcome measures, including the R-MBA and CGI-I.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### The 28 developmental milestones

| Domain | Milestones |
| --- | --- |
| Gross motor | “Come to sitting”; “Sat without support”; “Stood while holding on”; “Pulled to standing”; “Stood independently”; “Walked with support”; “Walked independently”; “Climbed up stairs with help”; “Climbed down stairs with help”; “Climbed up stairs without help”; “Climbed down stairs without help”; “Ran 10 feet without falling” |
| Fine motor | “Reached for toy”; “Holds bottle unpropped”; “Used raking grasp to retrieve an object”; “Used pincer grasp (refined or modified)”; “Transferred an object from one hand to another”; “Finger feed”; “Drank from a cup held without assistance”; “Used a fork or spoon to eat with assistance”; “Used a fork or spoon to eat without assistance” |
| Communication | “Pointed for something they wanted”; “Followed a command with a gesture”; “Identified body parts (pointed with eyes or fingers)”; “Followed a command without a gesture”; “Used word(s) with meaning”; “Spoke in phrases (2 words or more) with meaning” |

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Selection of the 28 milestones from the natural history study

> “Starting from 51 potential developmental milestones captured in the RNHS protocols (#5201, 2006–2014; #5211, 2015–2021)”
> “RNHS study principal investigators, RTT specialists, and caregivers identified milestones that were linked to activities of daily living and that were independently meaningful based on caregiver concept elicitation work”
> “Finally, milestones with higher likelihood of spontaneous gain in an untreated population were also excluded, resulting in a selected set of 28 milestones for analysis (Figure 1)”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Natural history: developmental plateau after 6 years of age in the Taysha-funded analysis

> “A clear developmental plateau emerged in children aged ≥6 years, after which spontaneous gain, and regain after sustained loss, was rare (first time gain <3% across milestones; Figure 3A; regain shown in Figure 3C)”
> “Time-since-loss parameters were important for interpretation of milestone regain because spontaneous regain likelihood varied as a function of time since milestone loss”
> “No consistent significant predictors of gain/regain were identified across the 28 milestones, such as”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### Natural history: skill gain, loss, and regain in 1228 females with classic Rett syndrome

> “The occurrence and time of gain, loss, and regain of 51 developmental skills was collected during in-person visits in the RTT Natural History Study from 1228 females with Classic RTT and a pathogenic loss-of-function variant in MECP2.”
> “Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.”
> “The lack of gain or regain of skills beyond 6 years old suggest that any functional gains in these skills after a clinical intervention would represent an important indicator of efficacy as a clinical trial endpoint in RTT.”
> “In this restricted set of developmental skills, the percentage of participants who gained at least one of these 38 skills fell below 5% per year after 6 years of life.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-3.1.1.6.1-7"></a>

###### Natural history: advantages of developmental endpoints in trials that cannot be double-blind

> “This is especially critical for clinical trials that preclude conducting studies in a double-blind fashion.”
> “The advantages of these developmental endpoints are: (1) they are easily defined, (2) binary, and (3) likely to be emergent with an effective treatment paradigm.”
> “trials to define the expected trajectory and likelihood of gain or regain in an untreated cohort as a comparator to participants in an open label trial.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-3.1.1.6.1-8"></a>

###### Natural history: earlier analysis of developmental skills

> “Early developmental skills were acquired by many, but clear differences from normal emerged, particularly in skills expected after age 6 months.”
> “These data may serve for planning and interpretation of early intervention studies in RTT.”

Source: [Neul et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4112822/)

<a id="topic-3.1.1.6.1-9"></a>

###### Psychometric validation of the RS-DMA in the RESUME study

> “The RESUME study is a U.S. based, non-interventional, and multisite longitudinal study designed to establish trial-ready video-capture and assessment methodologies in RTT”
> “Thirteen participants (N=13; Age: M=11.3, SD=4.7; CGI-S: M=4.9, SD=0.9) completed the RS-DMA, alongside other assessments, to evaluate the psychometrics and trial-readiness”
> “The RS-DMA met reliability criteria, as overall reliability of the RS-DMA was excellent across all items and raters (Fleiss Kappa= 0.82, 92.9% agreement, PABAK= 0.86)”
> “The RS-DMA met feasibility criteria, with a mean feasibility score of 8.27 (SD=1.17), indicating 83% of RS-DMA video recordings were deemed feasible for central rating”
> “The RS-DMA met fidelity criteria, with a mean score of 85.8% (SD=3.30%).”
> “100% of the 28 milestones were endorsed by a majority of caregivers as independently meaningful as a potential treatment response, after observing the RS-DMA”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### RS-DMA milestone with lower rater agreement: identifies body parts

> “Substantial to excellent agreement among central raters for 27 of the 28 individual RS-DMA milestones, and a fair level of agreement for the milestone”
> “Identifies body parts,”
> “due to challenges with feasibility when the eye-tracking overlay was not available (Table 1; Figure 3B)”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-11"></a>

###### RS-DMA historical caregiver interview compared with performative assessment

> “There was a range of Slight to Excellent agreement between the RS-DMA Historical Caregiver Interview vs performative RS-DMA with an average of 81.8% and more than a third of items rating at Slight or Fair”
> “Standardized in-clinic administration may result in type 2 errors (false negatives), which for truly disease modifying treatments is an acceptable potential signal loss in favor of controlling for type 1 errors (false positives)”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-12"></a>

###### Limitations of existing Rett syndrome outcome assessments for single-arm designs

> “Existing Clinical Outcome Assessments (COAs) in RTT are not well-suited as primary endpoints in single-arm designs using a PABA analysis framework”
> “as they cannot be bias-mitigated through blinded video review, lack a natural history anchored plateau, or rely on summary scores that lack sensitivity to individualized change”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-13"></a>

###### FDA interactions on the responder definition and the assessment

> “During advanced discussions with the FDA, reached alignment on the definition of a responder:”
> “gain/regain of ≥ one defined developmental milestone.”
> “The FDA provided guidance on an additional analysis to further support the responder definition, which the Company has completed and intends to submit, alongside the final protocol and statistical analysis plan (SAP), as part of the Investigational New Drug (IND) amendment.”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

> “The RS-DMA has been developed through multiple interactions with FDA who commented on”
> “the thoughtful approach taken in designing the Developmental Milestone Assessment (DMA) tool”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-14"></a>

###### Caregiver views on meaningful milestone gains

> “A total of 22 U.S.-based caregivers of individuals with classic Rett syndrome (aged 5–39 years) participated (Figure 1)”
> “Caregivers valued gain/regain of developmental milestones from gene therapy”
> “This data informed the use of the Developmental Milestone Assessment in a gene therapy clinical trial (REVEAL)”

Source: [Keeley et al. (2025)](https://tayshagtx.com/wp-content/uploads/Every-Gain-Expanding-Possibilities-Caregiver-Insights-on-Meaningful-Improvement-in-Rett-Syndrome-Gene-Therapy-GT.pdf)

<a id="topic-3.1.1.6.1-15"></a>

###### Key secondary endpoint instrument: Revised Motor Behavior Assessment

> “Using data from a natural history study (n = 1,075), we examined the factor structure, internal consistency, and validity of the clinician-reported Motor Behavior Assessment scale (MBA).”
> “The analysis resulted in a five-factor model: (1) motor dysfunction, (2) functional skills, (3) social skills, (4) aberrant behavior, and (5) respiratory behaviors.”
> “Further work is needed to evaluate this measure longitudinally and to add items related to the RTT phenotype.”

Source: [Raspa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7778880/)

<a id="topic-3.1.1.6.1-16"></a>

###### Key secondary endpoint instrument: Clinical Global Impression scales with Rett-specific anchors

> “Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study.”
> “Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.”

Source: [Neul et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4610825/)

<a id="topic-3.1.1.6.1-17"></a>

###### Validation status of Rett syndrome outcome measures

> “Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity.”
> “Validity data are not available although evidence of responsiveness was suggested in the paediatric Phase 2 [39] and 3 [14] trofinetide trials.”

Source: [Downs et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663341/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

> “The REVEAL pivotal trial is a single-arm, open-label trial that will enroll 15 females aged 6 to <22 years who are in the developmental plateau population of Rett syndrome.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.7.1-2"></a>

###### Sample size and power

> “Power analyses and bootstrap simulations supported a conservative natural-history-informed null threshold of 6.7% at a feasible sample size of N=15 under modeled trial-like sampling assumptions for aggregate responder analyses using milestone gain or regain”
> “Table 2: Power calculation indicates that a minimum of five responders would be required to reject the natural-history-informed null hypothesis with a sample size of 15”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Overenrollment to 17 participants

> “We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants to be analyzed at the interim analysis

> “The interim analysis to support the planned Biologics License Application (BLA) submission is expected to occur after all 17 patients complete six months of post-treatment follow-up.”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Null hypothesis and success threshold

> “A response rate of 33% (5 out of 15 patients) is the minimum threshold for success sufficient to reject the null hypothesis. Based on our natural history data analysis, the null hypothesis is that one out of 15 patients aged ≥ 6 years may gain/regain one of the 28 natural history defined developmental milestone without treatment, corresponding to a response rate of 6.7%.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “The response rate of 33% is the minimum threshold for success sufficient to reject the natural history established null hypothesis of 6.7%.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### Derivation of the 6.7% null threshold

> “The highest observed spontaneous gain rate after age 6 years was 3% which, at N=15, corresponded to 0.45 expected spontaneous responders; however, as responder rate must be discrete, one spontaneous responder (6.7%) was selected as the null threshold and evaluated across feasible sample sizes and responder counts using power calculations”
> “Across 10,000 simulations (N=15; ≥6 years of age), only 1.8% of simulations had ≥2 responders (Table 3)”
> “Across 150,000 simulated participants, this equated to a spontaneous responder rate of 1.39%”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Plateau-anchored, baseline-adjusted aggregate responder analysis

> “RNHS cumulative incidence estimates were used to construct the PABA aggregate responder framework by defining milestone eligibility and deriving a conservative natural-history-informed null threshold.”
> “Each milestone was assessed to determine the minimum time-since-loss at which spontaneous regain falls below the defined null threshold”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Primary analysis, interim analysis, and rater allocation by time point

> “SAP: 33% response rate is the minimum threshold for success sufficient to reject the null hypothesis of 6.7%”
> “12-month primary analysis FDA alignment on potential to submit BLA based on 6-month interim analysis”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

> “Figure 5: DMA implementation process in the REVEAL pivotal trial”
> “Raters will not see the same participant's videos back-to-back and will have maximum spacing to prevent direct comparisons.”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Participants dosed

> “Completed dosing in the overenrolled REVEAL pivotal trial, with a total of 17 females in the developmental plateau population of Rett syndrome dosed with TSHA-102”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.8.1-2"></a>

###### Acute post-dosing safety monitoring period completed

> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Age distribution of dosed participants

> “We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-related serious adverse event: peripheral sensory neuropathy

> “In July 2026, one patient in the REVEAL pivotal trial experienced a single, moderate Grade 2 technical classification of a treatment-related event of peripheral sensory neuropathy, an expected AAV-associated risk, approximately six weeks post-TSHA-102.”
> “In accordance with the treating institution’s protocol, the patient was admitted overnight for management and observation, thus, resulting in the technical classification of the Grade 2 event as an SAE.”
> “The patient was discharged the following day, and importantly, rapidly demonstrated substantial recovery. The patient has demonstrated continued meaningful improvement over the last three months and is almost back to baseline.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.8.5-2"></a>

###### Pooled safety across the REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE trials: November 2026 cutoff

> “High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Pivotal trial safety: June 2026 cutoff

> “TSHA-102 continues to be generally well tolerated, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported as of the June 2026 data cutoff”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Pivotal trial safety: March 2026 cutoff

> “There have been no treatment-related serious adverse events or dose-limiting toxicities across the participants treated with TSHA-102 in the REVEAL pivotal trial as of the March 2026 data cutoff.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
- Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
- Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
- Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
- Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
- Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
- Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
- Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
- Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
- Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [Taysha Gene Therapies second quarter 2025 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf); [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf); [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/); [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download); [Downs et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663341/); [Raspa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7778880/)

<a id="heading-3.1.2"></a>

#### 3.1.2 ASPIRE

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registry objective and official title

> “The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.”
> “ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females Aged >2 to <4 Years With Rett Syndrome”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.1-2"></a>

###### Regulatory purpose: safety data to support a label for patients aged 2 years and older

> “ASPIRE is designed to support a planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome.”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry record: dates, status, and sites

| Field | Quoted record |
| --- | --- |
| Protocol number | “TSHA-102-CL-201” |
| Study start | “2026-05-08” |
| Primary completion (estimated) | “2031-06” |
| Overall status | “Active, not recruiting” |
| Site | “University of Alabama at Birmingham” |
| Site | “Rush University Medical Center” |
| Site | “Boston Children's Hospital” |

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.2-2"></a>

###### FDA alignment and clearance to initiate

> “In January 2026, Taysha announced written alignment with the U.S. Food and Drug Administration (FDA) on the ASPIRE safety-focused trial and the data for inclusion in the planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome. Subsequently, the Company received FDA clearance to initiate the ASPIRE trial.”

Source: [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)

<a id="topic-3.1.2.2-3"></a>

###### Enrollment across multiple sites and dosing timeline

> “Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites; on track to complete dosing in REVEAL and ASPIRE in Q2 2026”

Source: [Taysha Gene Therapies first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm)

> “ASPIRE trial ongoing with enrollment exceeding the initial target of (N=3); on track to complete dosing of the three patients in Q2 2026 and expect to dose one additional patient in July 2026, further strengthening potential BLA submission for TSHA-102”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Single-group, open-label phase 3 design with blinded central raters

> “ASPIRE is an open-label study designed to evaluate the safety, tolerability and preliminary efficacy of TSHA-102 in 3 pediatric females aged 2 to less than 4 years old with typical Rett syndrome.”
> “The study comprises a screening period, TSHA-102 administration, a primary safety analysis period through 25 weeks post TSHA-102 administration, and an extended follow-up observation period through 5 years post TSHA-102 administration.”
> “Blinded central raters”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.3-2"></a>

###### Extrapolation design: efficacy from REVEAL pivotal, safety from ASPIRE

> “In close collaboration with the FDA we designed the TSHA-102 pivotal program so that efficacy data from the REVEAL pivotal trial in patients aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE trial to support the potential for a broad label for TSHA-102.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.2.3-3"></a>

###### Pre-developmental plateau population

> “Pre-developmental Plateau Population (females 2 to <4 years)”
> “Evaluate safety and preliminary efficacy; efficacy data to be extrapolated from pivotal trial”

Source: [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487)

<a id="topic-3.1.2.3-4"></a>

###### Earlier design: safety in children aged 2 to 6 years

> “Safety of TSHA-102 will be evaluated in females in the pre-developmental plateau population of Rett syndrome (2-6 years), with efficacy data extrapolated from the developmental plateau population”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria

> “Pediatric females between the ages of 2 and less than 4 years old.”
> “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.”
> “Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed.”
> “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.4-2"></a>

###### Exclusion criteria

> “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.”
> “Participant has a history of brain injury that causes neurological problems or had grossly abnormal psychomotor development in the first 6 months of life.”
> “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.”
> “Participant requires invasive ventilatory support.”
> “Note: Other protocol defined inclusion/exclusion criteria may apply”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Single intrathecal dose adjusted for brain volume

> “Participants receive a single intrathecal (IT) administration of TSHA-102 at 1.0 × 10¹⁵ total vector genomes (vg) adjusted for the participant's brain volume.”
> “TSHA-102 will be administered via lumbar puncture (LP).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary adeno-associated virus serotype 9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.5-2"></a>

###### High dose scaled to the lower brain volume of children aged 2 to less than 4 years

> “ASPIRE will enroll three females aged 2 to <4 years with Rett syndrome to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4‑year‑olds”

Source: [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint: treatment-emergent adverse events through week 25

> “Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”
> “Baseline through Week 25”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.6.1-2"></a>

###### Safety data requirement agreed with the FDA

> “Importantly, we recently reached written alignment with the FDA that our planned BLA submission will include at least three months of safety data from three patients aged two to under four years in the ASPIRE trial to support a broad label for patients aged two years and older with Rett syndrome.”

Source: [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal)

<a id="topic-3.1.2.6.1-3"></a>

###### Spontaneous milestone gain before 6 years of age limits efficacy assessment

> “Relatively high and variable rates of spontaneous first-time milestone gain were observed in children before 6 years of age, with rates as high as 97% in the youngest participants; most regain occurred within several years after loss, with milestone-specific variation (Figure 3A–C)”
> “Including participants younger than age 6 years may increase spontaneous milestone gain/regain rates and inflate type I error risk if not explicitly accounted for in the analysis framework”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

> “Up to 97% likelihood of spontaneous milestone gain before age 6 may create challenges in distinguishing treatment effect from spontaneous improvement”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### Regulatory framework: pediatric extrapolation and additional safety data

> “The principles underlying the appropriate use of data generated in a reference population(s) to define the scope and extent of efficacy data that needs to be collected in a target population can also apply to the generation of safety data (see section 4.1.7).”
> “Additional consideration as part of the pediatric extrapolation concept should be given to the collection of pediatric safety data in certain situations. Examples include:”
> “When the drug is a new molecular entity for a new class of drugs;”

Source: [ICH E11A guideline (2024)](https://database.ich.org/sites/default/files/ICH_E11A_Guideline_Step4_2024_0821.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment of three participants, overenrolled to four

> “Taysha has elected to overenroll the trial to include one additional screened and eligible patient and will now dose a total of four females with Rett syndrome, aged 2 to <4 years, to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4-year-olds”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.2.7.1-2"></a>

###### Dosing completed in four participants

> “Taysha completed dosing in the overenrolled ASPIRE trial, with a total of four patients with Rett syndrome, aged 2 to <4 years, dosed with TSHA-102.”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Four participants dosed; enrollment complete

> “A total of four participants were treated with the high dose (1×10¹⁵ total vg) of TSHA-102, scaled to account for the lower brain volume in 2 to <4 year olds. Enrollment for this trial is complete.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-3.1.2.8.1-2"></a>

###### All participants past the acute post-dosing monitoring period

> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Age at dosing

> “We have completed dosing of four patients aged 2 to <4 years with Rett syndrome in the overenrolled ASPIRE trial to evaluate the safety and preliminary efficacy of a single intrathecal administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4-year-olds.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Pooled safety across REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE as of November 2026

> “High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- ASPIRE is a multicenter, open-label study in which every participant receives TSHA-102. It dosed 4 participants (3 planned) aged 2 to less than 4 years, and the registry lists 3 sites.
- The registry primary endpoint is the proportion of participants experiencing any treatment-emergent adverse events and serious adverse events from baseline through week 25. The planned BLA is to include a minimum of 3 months of ASPIRE safety data, which is shorter than the 25-week primary safety analysis period and the 5-year follow-up period.
- No ASPIRE-specific safety results have been reported. The available safety statement pools 33 participants across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4) and reports the absence of severe treatment-related serious adverse events and dose-limiting toxicities as of the November 2026 data cutoff; it does not report the type or frequency of other adverse events in the 4 ASPIRE participants.
- No efficacy results have been reported. Efficacy in children aged 2 to less than 6 years is to be extrapolated from REVEAL pivotal participants aged 6 to less than 22 years in the developmental plateau population. The natural history analysis reports spontaneous first-time gain of a single milestone as high as 97% before 6 years of age, and states that including younger participants without explicit age accounting could increase background spontaneous gain.
- None of the three trials has dosed children aged 4 to less than 6 years: ASPIRE enrolls children aged 2 to less than 4 years, the 12 REVEAL Part A participants were 6 to 21 years of age at dosing, and REVEAL pivotal enrolls participants aged 6 to less than 22 years.
- The dose is 1.0 × 10¹⁵ total vector genomes adjusted for brain volume; no description of the scaling method or of the doses administered was identified.
- The registry states that other protocol-defined inclusion and exclusion criteria may apply, and no published protocol, statistical analysis plan, or description of analysis sets was identified.
- All information comes from the sponsor's registry record, press releases, and SEC filings and from a natural history analysis. The company's August 2026 corporate presentation describes efficacy data for females aged 2 to less than 4 years as to be extrapolated from the pivotal trial, while the Form 10-K and the third quarter 2026 Form 10-Q describe extrapolation to the 2 to less than 6-year-old population.

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm); [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm); [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 REVEAL Part A

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Objectives of the pooled REVEAL Part A analysis

> “To investigate the safety and preliminary efficacy of low- and high-dose TSHA-102 in adolescent/adult and pediatric females with Rett syndrome (RTT)”
> “Evaluate two dose levels to, if possible, establish maximum administered dose (MAD) or maximum tolerated dose (MTD)”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.1-2"></a>

###### Adolescent and adult trial (NCT05606614 Part A): registered objective

> “REVEAL Part A (Phase 1/2) is an open-label safety and dose-finding study designed to evaluate the safety and preliminary efficacy of two dose levels of TSHA-102 to establish initial safety of TSHA-102 and select a safe and efficacious dose for further evaluation.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.1-3"></a>

###### Pediatric trial (NCT06152237): registered objective

> “The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome.”
> “The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Adolescent and adult trial (NCT05606614): registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-03-06” |
| Primary completion (estimated) | “2031-06” |
| Study completion (estimated) | “2031-06” |
| Last update posted | “2026-07-07” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.2-2"></a>

###### Adolescent and adult trial (NCT05606614): registered sites for Parts A and B

| Country | Registry record |
| --- | --- |
| United States | “City of Hope” |
| United States | “UC San Diego” |
| United States | “UC San Francisco Benioff Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Kennedy Krieger Institute” |
| United States | “Boston Children's Hospital” |
| United States | “Washington University, St. Louis” |
| United States | “UT Southwestern Children's Medical Center” |
| Canada | “CHU St. Justine” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.2-3"></a>

###### Pediatric trial (NCT06152237): registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-12-12” |
| Primary completion (estimated) | “2028-11-02” |
| Study completion (estimated) | “2031-11-02” |
| Last update posted | “2025-10-15” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.2-4"></a>

###### Pediatric trial (NCT06152237): registered sites

| Country | Registry record |
| --- | --- |
| United States | “Rush University Medical Center & Children's Hospital” |
| United States | “Gillette Children's Specialty Healthcare” |
| United States | “Washington University, St. Louis” |
| Canada | “CHU Ste-Justine” |
| United Kingdom | “Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.2-5"></a>

###### First adult participant dosed in Canada, June 2023

> “DALLAS, June 05, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first patient has been dosed with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome.”
> “The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.”

Source: [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102)

<a id="topic-3.1.3.2-6"></a>

###### First pediatric participant dosed in the United States, January 2024, and United Kingdom authorization

> “Initial dosing in the REVEAL Phase 1/2 pediatric trial took place at RUSH University Medical Center in Chicago under Principal Investigator Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurology and Anatomy/Cell Biology at RUSH University Medical Center.”
> “The Company also announced the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Clinical Trial Application (CTA) for TSHA-102 in pediatric patients, enabling expansion of the ongoing U.S. REVEAL pediatric trial into the U.K.”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

<a id="topic-3.1.3.2-7"></a>

###### Expansion of the adolescent and adult trial into the United States, February 2024

> “The Company also announced the expansion of its ongoing REVEAL Phase 1/2 adolescent and adult trial in Canada into the United States (U.S.) following submission of the adolescent and adult trial protocol to the U.S. Food and Drug Administration (FDA).”
> “The trial is taking place in Canada and the U.S.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

<a id="topic-3.1.3.2-8"></a>

###### Completion of Part A dosing and data cutoffs

> “Dosing of the 10 patients with Rett syndrome in Part A, the dose escalation portion of the REVEAL Phase 1/2 adolescent/adult trial and the REVEAL Phase 1/2 pediatric trial, has been completed.”

Source: [Taysha Gene Therapies full-year 2024 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809dex991.htm)

> “As of May 2026 data cut, 12 patients (low dose, N=4; high dose, N=8) had received TSHA-102.”
> “Here, we present longer-term safety and efficacy data from REVEAL Part A, including all 12 patients with ≥12 months of follow-up, with data extending up to 30 months for the earliest treated patient”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Pooled design as reported with the 12-month results

> “REVEAL is an ongoing Phase 1/2, open-label, dose-escalation (Part A) and dose-expansion (Part B), registrational, multi-center trial, using each patient as their own control”
> “Safety monitoring included clinical/laboratory evaluations”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.3-2"></a>

###### Two first-in-human trials described together as Part A

> “The REVEAL Phase 1/2 Adolescent and Adult Trial, also known as Part A, is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in adolescent and adult females aged 12 years and older with Rett syndrome due to loss-of-function mutation in the methyl-CpG binding protein 2, or MECP2, gene.”
> “Part A also includes the REVEAL Phase 1/2 Pediatric Trial, which is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in pediatric females aged 5 to 8 years with Rett syndrome due to loss-of-function mutation in the MECP2 gene.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.3-3"></a>

###### Adolescent and adult trial (NCT05606614): registered design elements

| Design element | Registry record |
| --- | --- |
| Phase (record now covers Parts A and B) | “Phase 3” |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “Single (Outcomes Assessor)” |
| Masking description | “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.” |
| Follow-up | “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.3-4"></a>

###### Pediatric trial (NCT06152237): registered design elements

| Design element | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
| Study duration | “The study duration is up to 6 years.” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.3-5"></a>

###### Dose-escalation rules with Independent Data Monitoring Committee review (pediatric protocol design)

> “Part A is an open-label, single-arm dose-escalation study evaluating 2 doses of TSA-102 and is intended to define a maximum tolerated or maximum administered dose (MTD or MAD) (Figure 3).”
> “Finding of 1 DLT will trigger expansion of Cohort 1 to 6 participants; should two DLTs occur in Cohort 1, the initial dose will have surpassed the MTD.”
> “For outcomes with potential evaluator bias, participant videos will be assessed by independent experts blinded to participants’ treatment status.”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.3-6"></a>

###### Independent Data Monitoring Committee approval of dose escalation

> “The Independent Data Monitoring Committee (IDMC) approved the Company’s request to proceed to dose escalation in the REVEAL Phase 1/2 adolescent and adult trial, enabling earlier advancement to the high dose cohort of 1x1015 total vg.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

> “Received Independent Data Monitoring Committee (IDMC) approval to continue with enrollment in cohort two (high dose, 1x1015 total vector genomes (vg)) across both REVEAL Phase 1/2 trials, following review of available clinical data from the first two adolescent/adult patients and the first pediatric patient treated with the high dose of TSHA-102”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

<a id="topic-3.1.3.3-7"></a>

###### Part B design as planned before the pivotal trial replaced it

> “Patients will be randomized 3:3 to DTC or ITC in each Cohort in Part B”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria common to both trials

> “Females with pathogenic confirmation of MECP2 mutation”
> “Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at screening”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.4-2"></a>

###### Adolescent and adult trial (NCT05606614): registered criteria

> “Females between the ages of 12 and <22 in Part A (closed) and females between the ages of 6 and <22 in Part B (pivotal cohort).”
> “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.”
> “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment”
> “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.”
> “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.”
> “Participant requires invasive ventilatory support.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.4-3"></a>

###### Adolescent and adult trial: eligibility extended from adults to age 12 and older, November 2023

> “Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada”

Source: [Taysha Gene Therapies adolescent eligibility announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-expanded-eligibility-reveal)

<a id="topic-3.1.3.4-4"></a>

###### Pediatric trial (NCT06152237): registered criteria

> “Participant has a confirmed diagnosis of classical/typical Rett Syndrome with a documented mutation of the MECP2 gene that results in loss of function.”
> “Participant is between ≥5 to ≤8 years of age at the time of consent.”
> “Participant must be up to date with all relevant local vaccination requirements, with last vaccination dose received at least 42 days prior to the start of the immunosuppression regimen.”
> “Participant requires non-invasive and invasive ventilatory support.”
> “Participant has contraindications for IT administration of TSHA-102 or lumbar puncture procedure, other medical conditions, or contraindications to any medications required for IT administration.”
> “Participant has acute or chronic hepatitis B or C infections.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.4-5"></a>

###### Pediatric trial: stage three disease at entry

> “Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Registered dose levels (adolescent and adult trial)

> “TSHA-102 Dose Level 1: 5.7×10¹⁴ total vector genomes (vg). Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 1 (fully enrolled, 2 participants).”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (fully enrolled, 4 participants).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.5-2"></a>

###### Dose cohorts pooled across both trials

> “We have completed dosing of the 12 patients aged 6 to 21 years in Part A of both REVEAL trials, which includes eight patients in cohort two (high dose, 1x1015 total vector genomes, or vg) and four patients in cohort one (low dose, 5.7x1014 total vg).”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.5-3"></a>

###### Immunosuppression and intrathecal administration

> “Following immunosuppression initiation at Day −7, a single dose of TSHA-102 was delivered via intrathecal infusion through lumbar puncture on Day 0”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Immunoprophylaxis will begin at Day –7 and will be tapered from Week 17 to Week 25 (oral prednisolone) and starting from Week 38 (sirolimus).”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.5-4"></a>

###### Immunosuppression taper timing in the first two adult participants

> “Steroid taper completed Week 36, sirolimus taper completed Week 43”
> “Steroid taper completed Week 25, sirolimus taper completed Week 31”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.5-5"></a>

###### Low dose as stated before the first participant was dosed

> “Dose escalation will evaluate two dose levels of TSHA-102 sequentially, with an initial dose of 5x1014 total vector genomes (vg) and the second dose of 1x1015 vg.”

Source: [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102)

<a id="topic-3.1.3.5-6"></a>

###### Comparability of Part A clinical material with the commercial process

> “All process parameters and analytical results met predefined PPQ acceptance criteria and FDA-aligned comparability requirements, demonstrating that the final commercial process produces product comparable to the clinical material used in the REVEAL and ASPIRE trials.”
> “These results support the potential inclusion of REVEAL Part A data in the planned BLA submission, and we believe that the 6- and ≥12-month Part A results further support the potential for BLA submission based on the pivotal trial interim analysis.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary outcome: adolescent and adult trial

> “Part A: Safety and Tolerability of TSHA-102”
> “Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.6.1-2"></a>

###### Registered primary and exploratory outcomes: pediatric trial

> “The incidence of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions Improvement (CGI-I).”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Revised Motor Behavior Assessment (R-MBA).”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Rett Syndrome Behavior Questionnaire (RSBQ).”
> “The percent change from the steroid-free baseline period in monthly countable seizure frequency (MCSF).”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.6.1-3"></a>

###### Safety as the first objective of a first-in-human dose escalation

> “The REVEAL adolescent/adult (NCT05606614) and pediatric (NCT06152237) studies are first-in-human trials of TSHA-102 for individuals with Rett syndrome”
> “Safety (clinical and laboratory evaluations) and efficacy are being assessed through 18 months”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.6.1-4"></a>

###### Developmental milestone gain or regain as the primary evidence of efficacy

> “As established COAs and CROs are not optimal measures of functional outcomes in small, open-label trials, measuring gain/regain of DMs presents an objective, data-driven way to assess the efficacy of TSHA-102 in a broad Rett syndrome population”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Primary evidence of efficacy (DM gain or regain): Applied rigorous evaluation criteria to available video-evidenced DM data that enabled a reliable, objective assessment of TSHA-102 efficacy (Figure 4)”
> “Baseline: Video data/medical history confirming milestone was either never gained or lost sufficiently long ago, such that the likelihood of spontaneous gain/regain is <6.7%”
> “Evaluation method: Determined by multiple independent central raters based on prespecified definitions of achievement for each milestone”
> “A recent analysis of Natural History Study (NHS) data demonstrated that patients reach a developmental plateau at ≥6 years of age”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.6.1-5"></a>

###### Supplemental efficacy scales: MSEL-A, ORCA, and R-MBA

> “Supportive evidence of functional gain: Supplemental analysis of skills and improvements derived from structured assessments (MSEL-A, R-MBA, and ORCA) demonstrated additional functional skill gains and improvements across core disease characteristics outside of the natural history defined DMs”
> “Adapted Mullen Scales of Early Learning (MSEL-A): Centrally rated video-recorded evaluation assessing expressive / receptive language skills”
> “Observer-Reported Communication Ability (ORCA): Caregiver-reported structured evaluation assessing communication skills”
> “Revised Motor Behavior Assessment (R-MBA): Clinician-reported video evaluation assessing frequency, severity or independence of Rett syndrome characteristics”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.6.1-6"></a>

###### RSBQ removed after FDA feedback

> “Based on FDA feedback from ongoing discussions, the Company intends to focus on objective measures that clinically capture functional gains; the Rett Syndrome Behavior Questionnaire (RSBQ) will not be included as a primary or secondary endpoint in Part B of the REVEAL trials”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment per trial

> “Part A of the study will focus on determining Maximum Administered Dose (MAD) and Maximum Tolerated Dose (MTD) in at least six patients (three per dose) aged 5-8 years old.”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

> “Dosing in cohort one (low dose, n=2) is now considered complete.”
> “Dosing of the first patient in cohort two (high dose, n=3) of 1x1015 total vg expected in the second quarter of 2024.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

<a id="topic-3.1.3.7.1-2"></a>

###### Enrollment recorded in the registries

> “Enrollment of 6 participants in Part A is complete.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

| Field | Registry record |
| --- | --- |
| Enrollment (actual) | “6” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.7.1-3"></a>

###### Accrual over time

> “Dosed the third adolescent/adult patient in cohort two and enrolled the second pediatric patient in cohort two, with dosing scheduled for the current quarter”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

> “The dataset includes six patients in cohort two (high dose, 1x1015 total vector genomes (vg)) and four patients in cohort one (low dose, 5.7x1014 total vg).”

Source: [Taysha Gene Therapies full-year 2024 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809dex991.htm)

<a id="topic-3.1.3.7.1-4"></a>

###### Participants analyzed at the May 2026 data cutoff

> “REVEAL Part A efficacy data based on the May 2026 data cutoff included 12 females with Rett syndrome aged 6-21 years (high dose, n=8; low dose, n=4) treated with the high dose (1x1015 total vg) or low dose (5.7x1014 total vg) of TSHA-102, each with ≥12 months of follow-up”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

> “n=8 patients with ORCA data, n=7 with MSEL-A data, and n=12 with R-MBA data.”
> “N=12 at 6 and 12 months, N=7 at ≥18 months post-TSHA-102.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis set and data cutoff for the 12-month results

> “Statistical analyses are based on May 2026 data cutoff (N=12).”
> “R-MBA assessed in Rett syndrome NHS at ~6 and ~12 months; MBA natural history data converted to R-MBA; mean scores reported were calculated from baseline to 6 and 12 months”
> “Developmental milestone gains and regains were assessed by multiple independent central raters through video evidence.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Natural history comparator sample sizes for R-MBA

| Time point | TSHA-102 | Natural history |
| --- | --- | --- |
| 6 months | “TSHA-102 (N=12) SD=10.18” | “Natural History (N=75) SD= 5.97” |
| 12 months | “TSHA-102 (N=12) SD=8.86” | “Natural History (N=196) SD= 5.73” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Planned analysis relative to each participant's baseline (pediatric protocol design)

> “All Part A efficacy outcomes will be evaluated with descriptive statistics, relative to each participant’s baseline data.”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Earlier analyses drawn from the electronic data capture system

> “Data presented reflects current data in the Electronic Data Capture System, subject to change.”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### All 12 participants followed for at least 12 months

> “No treatment-related SAEs or DLTs observed in any patients, with all patients having ≥12 months of follow-up”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “The 12 patients treated in REVEAL Part A ranged from 6 to 21 years of age at dosing, with post-treatment follow-up spanning 12 to 30 months.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.8.1-2"></a>

###### Participants with data beyond 12 months

> “N=7 patients with data >12 months post-TSHA-102, N=5 patients with 12-month data.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Age, severity, and genotype of the 12 participants

> “Patients were 6‒21 YOA, with diverse clinical histories, broad disease severity (CGI-S 4 to 6), and varied MECP2 mutations to reflect a real-world population”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “Baseline scores ranged from 4 to 6, reflecting moderately to severely ill patients.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.8.2-2"></a>

###### Individual participants: age at dosing, baseline CGI-S, and follow-up

| Cohort and participant | Age at dosing (years) | Baseline CGI-S score | Post-treatment follow-up (months) |
| --- | --- | --- | --- |
| Low dose, participant 1 | “20” | “6” | “30” |
| Low dose, participant 2 | “21” | “4” | “30” |
| Low dose, participant 3 | “6” | “5” | “24” |
| Low dose, participant 4 | “7” | “4” | “24” |
| High dose, participant 1 | “15” | “5” | “18” |
| High dose, participant 2 | “21” | “5” | “18” |
| High dose, participant 3 | “8” | “5” | “18” |
| High dose, participant 4 | “15” | “5” | “12” |
| High dose, participant 5 | “16” | “5” | “12” |
| High dose, participant 6 | “6” | “4” | “12” |
| High dose, participant 7 | “7” | “6” | “12” |
| High dose, participant 8 | “6” | “5” | “12” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.2-3"></a>

###### First two adult participants: stage four disease

> “20-year-old female at the time of dosing”
> “21-year-old female at the time of dosing”
> “Large MECP2 deletion affecting exons 3 and 4”
> “Missense MECP2 mutation (R133C)”
> “Complete loss of ambulation and wheelchair-bound by age 8”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.2-4"></a>

###### First two pediatric participants: stage three disease

> “6-year-old female at the time of dosing”
> “7-year-old female at the time of dosing”
> “Nonsense MECP2 mutation (R255X)”
> “Missense MECP2 mutation (R306C)”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Responses at 6, 12, and at least 18 months (May 2026 data cutoff)

| Endpoint | 6 months (N=12) | 12 months (N=12) | 18 months or more (N=7) |
| --- | --- | --- | --- |
| Participants who gained or regained at least one developmental milestone | “83%” | “100%” | “100%” |
| Average functional gains per participant | “22” | “23” | “26” |
| R-MBA mean score change versus natural history | “-11.0 P = 0.0011” | “-10.3 P = 0.0002” | “-11.0 P = 0.0046” |
| Participants with CGI-I score of 3 or less at multiple post-treatment assessments | “100%” | “100%” | “100%” |
| Participants with CGI-S total score improvement | “25%” | “25%” | “57%” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-2"></a>

###### Developmental milestone response rate by time point

> “75% Response Rate (9/12)”
> “83% Response Rate (10/12)”
> “100% Response Rate (12/12)”
> “Response Rate = the % of patients who gain or regain ≥1 developmental milestone from a list of 28.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### Number of developmental milestones and additional skills

> “At ≥12 months post-TSHA-102, a total of 310 functional gains and improvements were observed (~26 per patient), comprising 31 DMs and 279 additional skill gains/improvements”
> “DM gains increased by 69% from 6 to 12 months and by 94% from 6 to ≥12 months post TSHA-102”
> “16 DMs in pediatric (n=6) and 15 DMs in adolescent/adult (n=6) patients support the broad treatment potential of TSHA-102”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “According to the MSEL-A (53 skill gains), ORCA (128 skill gains) and R-MBA (98 improvements).”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-3.1.3.8.3-4"></a>

###### Milestones achieved across domains

> “100% of patients gained/regained ≥one developmental milestone across the core functional domains of fine motor, gross motor and communication post-TSHA-102 (i.e., spoke in phrases with meaning, used utensils to eat without assistance, walked with support), as assessed by multiple independent raters through video-evidenced evaluation”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.3.8.3-5"></a>

###### R-MBA mean change from baseline versus natural history, by dose

| Time point | TSHA-102 mean change | Natural history mean change | P value |
| --- | --- | --- | --- |
| 6 months | “-11.0” | “-0.81” | “P = 0.0011” |
| 12 months | “-10.3” | “-0.62” | “P = 0.0002” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “-15.7 in high dose cohort”
> “-7.8 in low dose cohort”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-6"></a>

###### Dose comparison at the May 2025 data cutoff (10 participants)

| Endpoint | Low-dose cohort | High-dose cohort |
| --- | --- | --- |
| Developmental milestone responder rate at 6 months | “75%” | “83%” |
| R-MBA mean score improvement at 6 months | “-9.8” | “-12.2” |
| R-MBA mean score improvement at 9 months or more | “-11.5” | “-18.0” |
| Mean CGI-I score at 6 months | “2.3” | “2.0” |
| Mean CGI-I score at 9 months or more | “2.8” | “1.0” |
| Participants with CGI-S improvement at latest visit | “25%” | “33%” |

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Previously aligned-upon key design elements remain unchanged, including a 6-month interim analysis that may serve as the basis for the BLA submission, which was enabled by the rigorous, objective evaluation criteria used to evaluate developmental milestone achievement in Part A of the REVEAL Phase 1/2 trials, and the 83% response rate seen at six months post-treatment following high dose TSHA-102 (5 out of 6 patients; May 2025 data cutoff) that deepened over time.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.3.8.3-7"></a>

###### Supplemental analysis at the May 2025 data cutoff

> “A total of 165 additional skills/improvements were achieved across the 10 patients, further supporting the potential broad and consistent therapeutic impact of TSHA-102 on functional abilities and activities of daily living”
> “The scales include the Adapted Mullen Scales of Early Learning (MSEL-A) evaluating defined communication skills (N=5 patients with available data), the Revised Motor Behavior Assessment (R-MBA) evaluating specific Rett syndrome disease characteristics (N=10 patients with available data), and the Observer-Reported Communication Ability (ORCA) evaluating communication skills (N=5 patients with available data).”

Source: [Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053dex991.htm)

Additional sources: [Berry-Kravis et al. (2026b)](https://tayshagtx.com/wp-content/uploads/CNS-2026-REVEAL-12mo-data-encore-poster_approval.pdf); [Rossignol et al. (2025b)](https://tayshagtx.com/wp-content/uploads/Achieving-Developmental-Milestones-and-Broad-Restoration-of-Function-in-Rett-Syndrome-The-Potential-of-TSHA-102-Gene-Therapy.pdf); [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Caregiver-reported communication (ORCA)

> “Observer-Reported Communication Ability (ORCA): Caregiver-reported structured evaluation assessing communication skills”
> “n=8 patients with ORCA data, n=7 with MSEL-A data, and n=12 with R-MBA data.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “According to the MSEL-A (53 skill gains), ORCA (128 skill gains) and R-MBA (98 improvements).”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-3.1.3.8.4-2"></a>

###### Caregiver global impression (PGI-I) in the first adult participants

> “Global impressions show early (Week 4) improvement for both patients sustained through Week 52 for Patient 1 and Week 25 for Patient 2 as evaluated by clinicians and caregivers, respectively”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.4-3"></a>

###### Caregiver-reported behavior questionnaire (RSBQ)

> “The RSBQ is a 45-item questionnaire and is completed by the participant's Caregiver.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.8.4-4"></a>

###### Health-related quality of life instrument results

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)

| Event category | Low dose, participants | Low dose, events | High dose, participants | High dose, events | Total, participants | Total, events |
| --- | --- | --- | --- | --- | --- | --- |
| TEAE related to TSHA-102 | “4” | “17” | “5” | “20” | “9” | “37” |
| Serious TEAE unrelated to TSHA-102 | “3” | “9” | “4” | “8” | “7” | “17” |
| Serious TEAE related to TSHA-102 | “0” | “0” | “0” | “0” | “0” | “0” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.5-2"></a>

###### Most common treatment-related events, severity, and seizures

> “TSHA-102 was generally well tolerated at the low and high dose, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLT) (Table 1)”
> “All TEAEs considered related to TSHA-102 were mild-moderate in severity, with the most common being elevated liver enzymes* (n=4, 33%), CSF protein increased (n=3, 25%) (clinically insignificant), pyrexia (n=3, 25%)”
> “Includes preferred terms: Gamma-glutamyltransferase increased, Hypertransaminasaemia, Liver function test increased, Transaminases increased.”
> “Seizures have generally been well controlled following TSHA-102”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Transaminase pattern and other events at the May 2025 data cutoff

> “All TEAEs related to TSHA-102 were mild-moderate in severity, with the most common being elevated liver enzymes (N=4, 33%; includes hepatic enzyme increased, hypertransaminasemia, transaminases increased, and liver function test increased), pyrexia (N=3, 25%), lethargy (N=2, 17%), and elevated levels of NfL in CSF (clinically insignificant; N=2, 17%)”
> “Majority experience mild elevations <2x ULN”
> “Acute excursions (>5x ULN) less common, clinically asymptomatic and steroid treatment-responsive”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.8.5-4"></a>

###### Events in the first four low-dose participants, including immunosuppression-related events

> “TSHA-102 has been well tolerated with a total of 34 TEAEs as 05/10/2024. Of these, 33 were mild or moderate”
> “The most common AE overall was vomiting (5 TEAEs), a known risk of sirolimus”
> “Both patients had challenging side-effects related to immunosuppressant treatment.”
> “One serious adverse event, (severe, grade 3: change in seizure presentation) unrelated to TSHA-102, related to pre-existing disease and urine infection with multiple confounders (e.g., anesthesia, sleep deprivation)”
> “Eight nonserious events were related to immunosuppression (mild: vomiting (2), dermatitis acneiform, Cystatin C increase, blisters, myopathy) (moderate: chronic renal disease, myopathy)”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.5-5"></a>

###### Safety across Part A, the pivotal trial, and ASPIRE (November 2026 data cutoff)

> “TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”
> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

Additional sources: [Rossignol et al. (2024a)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-patients-with-Rett-Syndrome.pdf); [Taysha Gene Therapies low dose cohort data announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091dex991.htm)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
- No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
- Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
- Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
- Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
- Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
- Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
- Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
- Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053dex991.htm); [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf); [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf); [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102); [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical); [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed); [Taysha Gene Therapies adolescent eligibility announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-expanded-eligibility-reveal)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
